Avivagen Inc V.VIV.H

Alternate Symbol(s): VIVXF

Healthcare

Avivagen Inc. is a Canada-based life sciences company. The Company is focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance. The Company’s operations as one segment, products based on OxC-beta Technology. It OxC-beta technology is derived from its discoveries about B-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colors. OxC- beta Livestock is a proprietary product, an alternative to the antibiotics commonly added to livestock feeds. The product is available for sale in the United States, Mexico, Philippines, Taiwan, New Zealand, Thailand, Australia and Malaysia. It offers OxC-beta to approximately 46.6 million food animals (poultry, swine, and dairy cattle), 133,820 dogs and 4,000 people.

TSXV:VIV.H - Post by User

Avivagen Inc > New Financing

<< Previous

Bullboard Posts

Next >>

Comment by StoneMan45on Oct 15, 2020 9:29am

83 Views

Post# 31720214

RE:RE:New Financing

'...and the upcoming launch of its human nutraceutical product..'

Kym stated the human Nutraceeutical use would be launched before or by Nov 26th (Black Friday) 2020, so fairly soon..ish. Guess we'll see something more on this in about 6 weeks or sooner.

Avivagen Inc.

October 9 at 3:20 PM

 							Searching For Help In the Fight Against Coronaviruses

 							Collateral damage to the host caused by chronic or overzealous inflammation is also a significant factor in determining disease outcomes. Avivagen’s OxC-beta also can decrease chronic 
inflammation and limit the potential for overzealous inflammatory responses by actively reducing the level of cytokines and chemokines whose dysregulation is known to play a central role in perpetuating harmful inflammation. 


 													  													Avivagen Inc.
 													October 5 at 1:41 PM
  · 
 												 
 														With #covid19 heating up again we need to defend ourselves as soon as possible.
 														The earliest stages of the battle between a host and an invading pathogen is fought by the innate immune system. 
 														Avivagen’s published work in peer reviewed journals together with unpublished proof-of-concept studies shows that its OxC-beta product supports and primes the innate immune system while also dampening chronic, overzealous inflammatory responses, elements that could prove beneficial to those with heightened risk of infection with COVID-19, seasonal flu, the common cold, and future emerging diseases caused by novel pathogens. 